Pemphigus in dogs: An update

Introduction

Pemphigus in dogs is an autoimmune vesicobullous to pustular skin disease characterized by acantholysis (loss of adhesion between keratinocytes) with lesions restricted to the epidermis and typically located suprabasally or subcorneally depending on the variant. It most commonly presents as pemphigus foliaceus in middle-aged dogs, but several distinct clinicopathologic forms exist with differing target antigens, depth of acantholysis, lesion distribution, and prognosis.

Definition and Basic Concepts

 Pemphigus complex comprises autoimmune skin diseases in which IgG (sometimes IgA) autoantibodies target desmosomal adhesion molecules, leading to keratinocyte detachment and intraepidermal pustule/vesicle formation.  Lesions are confined to the epidermis, and each variant is defined by the level of epidermal cleavage (subcorneal vs suprabasal) and typical clinical distribution (face, mucosa, trunk, etc.).

Etiology and Pathogenesis

 There is a strong genetic predisposition in certain breeds (Akita, Chow Chow, Dachshund, Collie, Doberman, Newfoundland), and MHC class II/DLA alleles are suspected to underlie autoimmune dysregulation.  Environmental triggers include drugs (cephalosporins, sulfonamides), UV light, infections (molecular mimicry), stress, and neoplasia, which together with genetic factors promote immune dysregulation (↓Tregs, ↑Th2/Th17).  Autoantibodies are mainly directed against desmoglein-1 in pemphigus foliaceus, desmoglein-3 in pemphigus vulgaris, and in some cases desmocollin-1 or plakins (paraneoplastic pemphigus).

 Binding of these antibodies activates complement and recruits neutrophils and eosinophils, whose proteases and reactive oxygen species cause acantholysis, subcorneal/suprabasal clefting, neutrophil-rich pustules, and progressive crusting and lesion spread from face/pinnae to feet, trunk, and groin.

Classification and Key Variants

Clinical Features and Disease Activity Index

 Common clinical patterns include pustules, erosions, crusts, erythema, alopecia, and in PF loss of nasal cobblestoning with "hard pad" (erythematous swollen margins, cracking, villous hyperkeratosis) of footpads.  Mucosal involvement is rare in PF/PE but prominent in PV and PNP, where oral cavity (gingiva, palate, tongue) lesions are often severe and debilitating.  A canine pemphigus disease activity index scores lesion extent, lesion severity, pruritus/discomfort, mucocutaneous involvement, and systemic signs (0-3 or 0-5 scales), with total scores categorizing disease as remission/mild (0-4), mild-moderate (5-9), moderatesevere (10-14), or severe/life-threatening (≥15).  Rapid score increase indicates flare or inadequate control, while a > 50% decrease suggests an effective therapeutic response and can guide tapering decisions. Treatment: Conventional Immunosuppression  First-line therapy relies on glucocorticoids: oral prednisolone at 1-2 mg/kg once daily for 10-14 days, followed by tapering to 1 mg/kg every 48 h or less as control is achieved; topical low-potency steroids (1-2% hydrocortisone) can supplement localized lesions.  Alternatives/adjuncts include methylprednisolone (≈1 mg/kg PO q24h then EOD) or triamcinolone (0.1-0.3 mg/kg/day), which are more potent and may be used short-term to gain initial control.  Steroid-sparing agents: azathioprine (≈1.5-2.5 mg/kg q24-48h) suppresses T and B cell proliferation via purine antagonism but has delayed onset and requires monitoring for hepatotoxicity and myelosuppression.  Chlorambucil (0.1-0.2 mg/kg q24-48h) is an alkylating agent reserved especially for cats or dogs where azathioprine is contraindicated, functioning by DNA cross-linking and lymphocyte suppression.

Diagnosis and Recent

 Tetracycline-niacinamide combinations (250-500 mg of each q8h depending on body weight) provide mild anti-inflammatory and immunomodulatory effects and can be used in mild cases or as part of maintenance.  Throughout therapy, secondary bacterial infections must be controlled with appropriate systemic or topical antimicrobials based on culture and sensitivity when possible.

Newer and Alternative Therapies  Calcineurin inhibitors (cyclosporine 5-10 mg/kg q24h and topical 0.1% tacrolimus BID) suppress T-cell activation by inhibiting IL-2 and can be effective in steroid-refractory cases or localized lesions like nasal planum or periocular skin.  Mycophenolate mofetil (about 8-12 mg/kg BID or 22-39 mg/kg/day divided) inhibits de novo purine synthesis in lymphocytes, offering potent immunosuppression but with GI adverse effects and variable efficacy.  Dapsone (≈1 mg/kg BID-TID) reduces neutrophil myeloperoxidase activity and reactive oxygen species and is useful in neutrophilic dermatoses such as PF, but carries risk of hemolysis and methemoglobinemia.  Oclacitinib (0.4-0.6 mg/kg BID then SID) as a JAK1

inhibitor has a limited direct role in pemphigus but may alleviate pruritus and inflammation, and in combination with glucocorticoids has shown slightly better lesion reduction than glucocorticoid-azathioprine protocols in PF dogs.  Bruton's tyrosine kinase inhibitors (PRN-473 and PRN-1008) have reduced clinical signs and anti-Dsg1 antibody levels in canine PF, suggesting they may become glucocorticoid-sparing alternatives.  Therapeutic plasma exchange has achieved around 50% reduction in lesional body surface area in PF dogs, but remains experimental and requires further study for routine clinical use.  Chrysotherapy (gold salts such as oral auranofin 0.05-0.2 mg/kg q12h or injectable 1 mg/kg weekly) has immunomodulating and anti-inflammatory properties and can be used as adjunctive or alternative therapy in refractory cases.  Pulse glucocorticoid therapy (e.g. 10 mg/kg for 3 days then <2 mg/kg with repeat pulses as needed) and use of methylprednisolone as first-line have been associated with faster remission than traditional constant-dose regimens.

Treatment Phases and Monitoring

 Induction phase aims for rapid suppression of inflammation and autoimmunity using higher immunosuppressive doses until clear remission (no new lesions, healing of existing lesions) is achieved.  Transition phase entails slow tapering of drugs over weeks to months to identify the minimum effective dose while avoiding relapse; if flare occurs, doses are increased and the induction phase is essentially repeated.  Maintenance phase uses the lowest dose and frequency that keep the patient symptom-free, often with EOD steroid dosing plus one or more steroid-sparing agents.  A dog is considered "cured" only when it has achieved remission, remains controlled on maintenance therapy, and does not relapse after complete discontinuation of treatment.

Prognosis

 Overall prognosis for pemphigus foliaceus and erythematosus is usually fair to good, especially with early diagnosis, aggressive induction, and careful long-term monitoring.  PV and PNP carry guarded to poor prognosis because of severe mucosal disease, systemic illness, tumor associations, and frequent refractoriness to therapy.  Relapses are common across the pemphigus complex, necessitating client education about the chronic, often lifelong nature of immunosuppressive management.

Aggressive glucocorticoid therapy, exploring different glucocorticoid options, and integrating newer targeted or adjunctive therapies can improve long-term control and quality of life in affected dogs.

References

1. Olivry T. A review of autoimmune skin diseases in domestic animals: Pemphigus complex. Vet Dermatol. 2006;17(5):291-305.
2. Bizikova P, Olivry T. Clinical and histopathological features of canine pemphigus foliaceus. Vet Dermatol. 2014;25(3):180-e45.
3. Gross TL, Ihrke PJ, Walder EJ, Affolter VK. Skin diseases of the dog and cat: Clinical and histopathologic diagnosis. 2nd ed. Oxford: Blackwell Science; 2005.
4. Rosenkrantz WS. Pemphigus: Current therapy in veterinary dermatology. Vet Clin North Am Small Anim Pract. 2004;34(3):623-637.
5. Mueller RS, Krebs I, Power HT, Fieseler KV. Pemphigus foliaceus in dogs: A retrospective study of 91 cases. Vet Dermatol. 2006;17(4):207-214.